HIMS & HERS HEALTH INC (HIMS)
US4330001060 - Common Stock
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers stock is full of noise, but what's the signal for investors?
Noteworthy Thursday Option Activity: EXE, OMER, HIMS
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Compounders now have until late March to wind down their operations, depending on their licensing.
Is NYSE:HIMS suited for growth investing?
HIMS & HERS HEALTH INC (NYSE:HIMS) may be suited for growth investing, we'll explore why in this article.
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Top Buys by Directors: Manuel's $132.3K Bet on HIMS
The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About Weight
January 2025 Options Now Available For Hims & Hers Health (HIMS)
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
Hims & Hers Named to Inc.’s 2024 Best in Business List in Health Products Category
Why Hims & Hers Stock Jumped on Massive FDA News
Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.
Hims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally
Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.
Noteworthy Friday Option Activity: HIMS, AMBA, VZ
Hims & Hers New Growth Category Is a Huge Surprise
Is the food business the right business for Hims & Hers to be in?
Hims & Hers Expands Nutrition Support to Fuel Customers’ Weight Loss Journeys
January 2025 Options Now Available For Hims & Hers Health (HIMS)
